Eli Lilly and Company reported positive topline results from its TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational weight-loss drug met all primary endpoints in adults with obesity. Study participants also had type 2 diabetes or established cardiovascular disease.
Patients achieved average weight reductions of 20.8% in the TRIUMPH-2 study. The TRIUMPH-3 trial showed an average weight loss of 22.6%. Retatrutide functions as a first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon.
Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. This timeline follows the completion of the full data package. The drug positions the company to compete more aggressively against Novo Nordisk in the weight-loss market. Company shares rose in pre-market trading on Thursday following the announcement.